Northwest Biotherapeutics (NWBO) Profit After Tax (2010 - 2026)

Northwest Biotherapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$2.9 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 86.34% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at -$47.5 million (up 45.13% YoY), while the FY2025 annual figure was -$60.2 million, up 28.11% from the prior year.
• Profit After Tax for Q1 2026 stood at -$2.9 million, down from $1.4 million in the prior quarter.
• The five-year high for Profit After Tax was $1.4 million in Q4 2025, with the low at -$32.9 million in Q3 2022.
• The 5-year median for Profit After Tax is -$19.2 million (2025), against an average of -$19.0 million.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax tumbled 772.74% in 2022, then jumped 104.93% in 2025.
• Northwest Biotherapeutics' Profit After Tax stood at -$28.3 million in 2022, then surged by 38.65% to -$17.4 million in 2023, then slumped by 62.04% to -$28.1 million in 2024, then surged by 104.93% to $1.4 million in 2025, then tumbled by 309.22% to -$2.9 million in 2026.
• Business Quant data shows NWBO's Profit After Tax at -$2.9 million in Q1 2026, $1.4 million in Q4 2025, and -$26.8 million in Q3 2025.